Recently, Yen et al. [29] published an emulated target trial study to compare the risk of dialysis, cardiovascular events, and death between users and non-users of SGLT-2 inhibitors in patients with T2DM and stage 5 CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.